A blend usually described as GHK-Cu, BPC-157, and TB-500. People discuss it for skin and recovery.
5-minute readFull profile reviewed July 25, 2026
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
GLOW blend at a glance
Why people look into it, what studies found, and what is still unknown.
Why people look into it
Whether combining these ingredients produces a useful repair or skin effect.
What studies found
No controlled human study of the three-ingredient blend was located. Findings for individual ingredients do not prove the blend works.
What is still unclear
Ingredients and ratios may vary. Combined effects, interactions, stability, and safety remain unknown.
About the evidence and review date
Educational information only. Evidence reviewed through July 25, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Why people research it
Each label shows how much evidence supports that question.
Skin appearance and repairIngredient studies only
Wound and injury recoveryIngredient studies only
Inflammation researchIngredient studies only
Benefit from the combined blendNot demonstrated
What studies show
What the evidence supports
The research behind the answer
None for GLOW as a blend. The strongest component-level human evidence
comes from specific topical GHK-Cu studies; it cannot establish
injectable GLOW.
See each finding and its sources (8)
No direct evidence located
GLOW is an informal blend label, not a standardized active pharmaceutical ingredient.
Peptide Relay uses GLOW to organize discussion of mixtures labeled as GHK-Cu, BPC-157, and TB-500. The name does not define a regulator-recognized identity, fixed ratio, formulation, or quality standard.
A label alone cannot verify what a particular product contains. Composition and ratios may vary.
Relay identity definition: This statement defines how Relay organizes a nonstandard market label. It is not an empirical outcome claim or verification of any product's contents.
No direct evidence located
No peer-reviewed or registered study of the exact GHK-Cu, BPC-157, and TB-500 combination was located.
Searches of PubMed and ClinicalTrials.gov through July 25, 2026 did not identify a study administering all three together.
A no-results search is time-limited and cannot prove that no unpublished use has occurred.
Ingredient evidence cannot be added together to predict GLOW's benefit.
The three component records involve different routes, formulations, evidence levels, populations, and endpoints. Separate findings do not demonstrate synergy or a combined clinical effect.
Mechanistic plausibility is not a substitute for testing the actual mixture.
Human evidence is uneven across the three components and does not establish injectable GLOW.
GHK-Cu has mixed formulation-specific topical human research; BPC-157 has small uncontrolled reports and a registered Phase 2 trial without results; FDA found no human TB-500 administration by any route.
This is an evidence map, not evidence that the ingredients or the blend are effective.
The small BPC-157 plus thymosin-beta-4 knee report is not evidence for GLOW.
Only four people received the two-material treatment, no one received GHK-Cu, there was no comparison group, and the report does not establish that its thymosin-beta-4 material was the seven-amino-acid TB-500 fragment.
Self-reported improvement in an uncontrolled four-person subgroup cannot isolate a combination effect.
Peer reviewedMethods, intervention groups, and reported outcomes
No evidence establishes GLOW synergy, compatibility, receptor complementarity, or absence of interaction.
Different proposed pathways do not show that the ingredients remain chemically stable together, avoid aggregation, or produce a favorable biological interaction.
Absence of a known receptor overlap or reported interaction is not evidence of compatibility or safety.
Regulatory sourcePeptide aggregation, impurity, immunogenicity, and limited-human-data concerns
No direct evidence located
No approved dose, route, reconstitution method, or storage condition exists for GLOW.
No regulator-approved fixed-combination product or combination study provides a universal preparation, administration, or handling process.
Instructions for one component or one formulation cannot be transferred to a mixture.
GLOW is not FDA approved, and component-level compounding actions do not approve the blend.
GHK-Cu, BPC-157, and TB-500 have different regulatory histories. Advisory votes or category placement for an ingredient do not establish approval, safety, effectiveness, or eligibility of a fixed combination.
Regulatory and compounding status can change and should be checked ingredient by ingredient.
Relay has not verified a clear pattern of side effects for this compound.
Evidence boundary
Human exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
Missing reports do not establish safety. Findings apply to the product, route, amounts, population, comparison, and follow-up studied.
Side-effect frequency, study withdrawals, and gaps
How often side effects occurred
The available information does not reliably show how often particular side effects occur.
Evidence boundary
Under-detected or under-reported events must not be described as rare.
Why people stopped in studies
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundary
This is an evidence gap, not proof that discontinuations did not occur.
Warning information
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundary
No FDA-approved GHK-Cu/BPC-157/TB-500 fixed-combination product was
located. Ingredient-level compounding reviews and advisory actions do
not approve the blend.
The blend's actual identity and ratio, chemical and physical
compatibility, stability after mixing, sterility, pharmacokinetics,
interactions, immunogenicity, dose-response, safety, and clinical
effects.
Emergency instructions
This profile does not contain verified, product-specific emergency instructions.
Evidence boundary
Relay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Dosing & preparation
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Route: Route unverified · No exact human administration route established in this review
Evidence gap · Route unverified
No verified regimen for this exact identity
GLOW is a blend name, not one standardized formulation. Studies of BPC-157, GHK-Cu, or thymosin-related components do not establish a combined dose or ratio.
What would fill this gap: A defined composition and direct combination-specific human protocol.
Dosing review checked Oct 20, 2026. Additional sources are available below.
Formulation & handling · Route unverified
No route-specific preparation instructions were verified. A different route or product does not supply them.
Starting dose, maintenance, and trial targets explained
Starting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
Other source records, populations, and limits · all routes
No direct study for this identity
GLOW fixed-combination evidence
Amount in this source
A complete human regimen was not verified in this source record. See the dosing status above.
Frequency
Not established in published research
Route
No verified route for a standardized GLOW formulation
Duration
Not established in the reviewed record
Population, study design, and limitations
No verified study was located that administered GHK-Cu, BPC-157, and TB-500 together as one reproducible GLOW formulation. Separate ingredient records are not a combination study.
Population: No directly studied human population was verified for this identity.
Design: No direct controlled or registered blend study located
Component studies use different identities, routes, formulations, populations, and outcomes.
The section remains incomplete because blend-specific compatibility, exposure, safety, and outcome evidence do not exist in the reviewed record.
No direct primary administration source was verified for this exact identity.
Mechanisms
How it works
The proposed components differ in identity, formulation, and evidence
maturity. GHK-Cu is a copper-binding tripeptide with mixed,
condition-specific topical human evidence. BPC-157 is a synthetic
pentadecapeptide with predominantly preclinical evidence, small
uncontrolled human reports, and a registered Phase 2 trial without
results. TB-500 is an N-acetylated seven-amino-acid thymosin-beta-4
fragment for which FDA located no human administration. No
pharmacokinetic, stability, compatibility, interaction, safety, or
efficacy study of the exact three-component combination was located.
Why this matters
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Signals and targets
No validated direct GLOW targetNo validated molecular target for BPC-157No validated cell-surface receptor for GHK-CuNo established human pharmacologic target for TB-500
Proposed biological steps
GHK-Cu: copper binding and extracellular-matrix signaling
BPC-157: proposed vascular, fibroblast, nitric-oxide, and inflammatory signaling
TB-500: proposed actin-region biology based on a seven-amino-acid fragment
No demonstrated blend mechanism or synergy
Research reference
How mature is the evidence?
A reference for the studies, populations, and routes behind this profile.
Research depthNo direct blend program
The available record consists of separate-component evidence and documented searches that found no exact-combination study.
Why this matters
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Evidence confidenceVery low for blend outcomes
No direct evidence establishes benefit, synergy, compatibility, stability, safety, or pharmacokinetics for the three-component mixture.
Why this matters
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
Strongest evidenceSeparate-component studies only; none administered the defined GLOW blendWhy this matters
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human evidenceNo verified direct human GLOW study locatedWhy this matters
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
Which product or study does this describe?
GLOW fixed-combination evidence: amounts and schedules describe this route record only.
Route studiedNo verified route for a standardized GLOW formulation
Schedules studiedNot established in published research
Amounts studiedWithheld: this record provides research context without a transferable amountWhy this matters
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-lifeNot established for this exact editorial recordWhy this matters
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Route evidenceNo verified study was located that administered GHK-Cu, BPC-157, and TB-500 together as one reproducible GLOW formulation. Separate ingredient records are not a combination study.Why this matters
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Component studies use different identities, routes, formulations, populations, and outcomes. The section remains incomplete because blend-specific compatibility, exposure, safety, and outcome evidence do not exist in the reviewed record. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study-by-study record
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
Why this matters
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Controlled human studyPeer reviewed
Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper
Randomized topical GHK-Cu program with standardized diabetic-ulcer care
Adults with diabetic neuropathic plantar ulcers
Outcomes measured
Complete ulcer closure
Time to closure
Ulcer-area reduction
Adverse events
What was reported
An immediate-treatment plantar-ulcer analysis reported more complete closure with topical GHK-Cu than vehicle.
Study administration and important limits
Study administration: Topical GHK-Cu gel plus wound care versus vehicle plus wound care
Limitations: This tested a topical GHK-Cu formulation in a defined wound population. It does not test BPC-157, TB-500, injection, mixing, or the GLOW combination.
Laboratory studyPeer reviewed
Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats
PhasePreclinical component evidence — not a GLOW study
PopulationNot disclosed
DurationIn-vitro incubations and rat urine collection through 72 hours
Design and population
TB-500 metabolism in human-derived in-vitro systems and rats, with fibroblast scratch-wound assays
Human serum and microsomal systems, cultured fibroblasts, and rats
Outcomes measured
Peptide and metabolite identification
Fibroblast scratch-wound closure
Cell viability
What was reported
Parent TB-500 did not improve fibroblast scratch-wound closure at the tested concentration; one shorter metabolite showed activity.
Study administration and important limits
Study administration: TB-500 free base and synthesized metabolites under laboratory protocols
Limitations: This is laboratory and animal component evidence. It does not establish human TB-500 benefit or any finding for a three-component mixture.
Other human evidencePeer reviewed
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
PhaseSmall retrospective report — not a GLOW study
Population16 participants
DurationFollow-up timing was not standardized
Design and population
Uncontrolled retrospective report of intra-articular treatment for knee pain
16 people with several types of knee pain
Outcomes measured
Self-reported knee-pain relief
What was reported
Fourteen of 16 people reported relief overall. Three of the four people in the two-material subgroup reported relief.
Study administration and important limits
Study administration: Twelve received BPC-157 alone; four also received material described as thymosin beta-4. No GHK-Cu was used.
Limitations: There was no control group, standardized outcome assessment, or GHK-Cu. The four-person subgroup cannot establish a combination effect, and material described as thymosin beta-4 is not verified as the seven-amino-acid TB-500 fragment.